FDA approves AbbVie’s Juvmo for Parkinson’s

The FDA approved AbbVie’s once-daily Parkinson’s disease treatment Juvmo (tavapadon) for adults. The drug partially activates dopamine D1 and D5 receptors, aiming to ease symptoms associated with declining dopamine. Phase 3 trials found improvements in motor symptoms and daily motor function among people with early Parkinson’s and those experiencing motor fluctuations while taking levodopa; common side effects included nausea, headache and dizziness. AbbVie gained the drug through its 2023 acquisition of Cerevel Therapeutics.